ID   OCM-1A
AC   CVCL_6935
SY   OCM1A; OCM1a
DR   cancercelllines; CVCL_6935
DR   Cosmic; 1247863
DR   GEO; GSM1082693
DR   Wikidata; Q54931806
RX   PubMed=15299072;
CC   Problematic cell line: Contaminated. Parent cell line (OCM-1) has been shown to be a M14 derivative.
CC   Population: Caucasian.
CC   Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; c.150+2T>C (IVS1+2T>C); ClinVar=VCV000406712; Zygosity=Heterozygous; Note=Splice donor mutation (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; c.455insCdel26; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly266Glu (c.797G>A); ClinVar=VCV000161516; Zygosity=Heterozygous (from parent cell line).
CC   Miscellaneous: Formerly the CCRID database had an entry describing this cell line (3111C0001CCC000234). It was one of the sources for the STR profile of this entry.
CC   Derived from site: Metastatic; Right buttock, hypodermis; UBERON=UBERON_0013691+UBERON_0002072.
ST   Source(s): CCRID
ST   Amelogenin: X
ST   CSF1PO: 11
ST   D13S317: 12
ST   D16S539: 9
ST   D18S51: 13,18
ST   D19S433: 14,15
ST   D21S11: 30
ST   D2S1338: 19
ST   D3S1358: 14,16
ST   D5S818: 11,12
ST   D7S820: 8,10
ST   D8S1179: 13
ST   FGA: 21
ST   TH01: 6,7
ST   TPOX: 8,11
ST   vWA: 18
DI   NCIt; C3802; Amelanotic melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_6934 ! OCM-1
SX   Male
AG   33Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 21
//
RX   PubMed=15299072; DOI=10.1158/1535-7163.895.3.8;
RA   Qin J.-Z., Stennett L., Bacon P., Bodner B., Hendrix M.J.C.,
RA   Seftor R.E.B., Seftor E.A., Margaryan N.V., Pollock P.M., Curtis A.,
RA   Trent J.M., Bennett F., Miele L., Nickoloff B.J.;
RT   "p53-independent NOXA induction overcomes apoptotic resistance of
RT   malignant melanomas.";
RL   Mol. Cancer Ther. 3:895-902(2004).
//